IceCure Medical Ltd. has signed an exclusive distribution agreement with Scovas Medical for its ProSense® cryoablation systems in the Netherlands. This agreement supports the commercialization and access to minimally invasive breast cancer treatments in the region as cryoablation technology advances.
Company Information
Company
IceCure Medical
Location
7 HaEshel Street
Caesarea, Haifa District, Israel
About
IceCure Medical (NASDAQ: ICCM) develops and markets advanced liquid-nitrogen-based cryoablation therapy systems for the destruction of tumors (benign and cancerous) by freezing, with the primary focus areas being breast, kidney, bone and lung cancer. Its minimally invasive technology is a safe and effective option to surgical tumor removal that is easily performed in a relatively short procedure. The Company's flagship ProSense® system is marketed and sold worldwide for the indications cleared and approved to date including in the U.S., Europe and Asia.
CaesareaManufacturingBiotechnologyHealth CareMedicalMedical Devicemedical devices